| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Internal Medicine, Endocrinology, and Metabolic Diseases (N.P., R.G., G.D.P.), Department of Emergency and Organ Transplantation, and Psychiatry (A.C., P.D.G.), Department of Neurological and Psychiatric Sciences, University of Bari, 70124 Bari; and Internal Medicine (R.V., G.M., M.G., G.F.), Department of Medical and Surgical Sciences, University of Padova, 35128 Padova, Italy
Address all correspondence and requests for reprints to: Giovanni De Pergola, M.D., via Putignani 236, 70122 Bari, Italy. E-mail: g.depergola{at}endo.uniba.it.
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
It has been recently demonstrated that adipose tissue serves not only as an energy storage organ but also secretes hormones and metabolites that are thought to regulate insulin sensitivity and energy metabolism (2). Indeed, the term "adipocytokines" was recently coined to describe the adipose-derived bioactive factors modulating the physiological functions of other tissues. Some well known examples among these factors include leptin and adiponectin.
Leptin, a 167-amino-acid protein encoded by the obese (ob) gene (3), is expressed almost exclusively in adipose tissue (4), from which it is secreted into the circulation and transported to the hypothalamic area, where it acts as a lipostatic mechanism, modulating satiety and sympathetic nervous system-mediated energy expenditure. Plasma leptin concentrations are strongly related to body fat mass in lean and obese subjects, increase in the fed state, and decrease rapidly during nutritional deprivation (5, 6).
Adiponectin is a 244-amino acid protein with high structural homology to collagen VIII, collagen X, complement C1q (7, 8), and TNF (9). It is produced by the most abundant gene in adipose tissue, the apM1 gene, which is exclusively and abundantly expressed in white adipose tissue. In contrast to all other adipocytokines known to date, plasma adiponectin concentrations were found to be decreased, not increased, in obesity and type 2 diabetes, conditions commonly associated with insulin resistance and hyperinsulinemia (10).
The role of adiponectin in later development of type 2 diabetes has been recently assessed in a longitudinal study in the Pima Indian population. Individuals with high concentrations of this protein were less likely to develop type 2 diabetes than those with low concentrations, thus supporting the hypothesis that adiponectin has a key role in the progression from obesity to type 2 diabetes (11). Moreover, it has been shown that, both in obese rats (12) and in humans (13), body weight reduction increased plasma adiponectin despite the reduction of the only tissue of its own synthesis. Interestingly, Havel et al. (14) recently reported a significant increase of plasma adiponectin in normal-weight young adult women, in response to 7 d of energy restriction (
600 kcal/d). On the contrary, depletion of adipose tissue in mice, after treatment with a peroxisome proliferated-activated receptor/retinoid-X receptor inhibitor, resulted in complete absence of adiponectin and in severe insulin resistance, fully reversible with supplementation with this adipocytokine (15).
On this basis, the profound loss of adipose tissue, caused by prolonged starvation in AN, is likely to be associated with changes in adipocytokines secretion and/or concentration and, consequently, in energy metabolism and insulin-stimulated glucose disposal. Indeed, a significant decrease in plasma leptin levels has been shown to occur in AN (16), thus suggesting that this fall in ob protein circulating concentrations may be involved in the neuroendocrine adaptation to starvation (17). As for adiponectin, to the best of our knowledge, there are no available data concerning the effect of AN on circulating levels of this adipose-specific protein.
Therefore, in the current study, we examined the effects of AN on adipocytokines (leptin and adiponectin) plasma concentrations and insulin-stimulated glucose disposal (as measured by the euglycemic-hyperinsulinemic glucose clamp technique) in adolescent and young adult women.
| Subjects and Methods |
|---|
|
|
|---|
The mean age of the anorectics was 20.6 ± 5.8 yr and was not significantly different from the mean age of 24.6 ± 6.2 yr of the healthy female controls (P = 0.076).
All subjects were measured, in the fasting state, early in the morning, on d 57 of the menstrual cycle in control subjects; all the AN patients were amenorrheic. The study protocol was reviewed and approved by the ethics committee of the University of Bari School of Medicine and was performed in accordance with the guidelines proposed in the Declaration of Helsinki.
Height and weight were determined according to the standard procedure (19). Height was measured, to the nearest 0.1 cm, with a wall-mounted stadiometer. Weight was recorded to the nearest 0.01 kg by using a calibrated computerized digital balance; each subject was barefoot and wore a light bathing suit.
Plasma leptin was measured by a specific RIA, which has been previously described in detail (6, 20). Sensitivity was 0.03 ng/liter, and the intra- and interassay coefficients of variation were 0.8% and 8.5%, respectively.
Plasma adiponectin was measured by a specific RIA obtained from Linco Research, Inc. (St. Charles, MO), with minor modifications. Recombinant human adiponectin was used as standard, and a multispecies adiponectin rabbit antiserum was used. The assay buffer contained 10.0 mmol phosphate buffer, pH 7.6, sodium azide (0.09%) and BSA (0.15%). The intra- and interassay coefficients of variation were 3.3% and 8.4%, respectively.
Plasma glucose was determined by the glucose-oxidase method (Sclavo, Siena, Italy).
Insulin action was assessed, at physiological insulin concentrations, during a hyperinsulinemic-euglycemic glucose clamp, as previously described (21). In brief, after an overnight fast, a primed continuous iv insulin infusion was administered at a constant rate of 40 mU/m2 body surface area·min, leading to steady-state plasma insulin concentrations. Plasma glucose concentration was maintained at approximately 5.5 mM, with a variable infusion of a 50% glucose solution. The rate of total insulin-stimulated glucose disposal was calculated for the last 40 min of insulin infusion. Indirect calorimetry (Vmax 29N System; SensorMedics Corporation, Yorba Linda, CA) was used, during the last 60 min of the insulin clamp, to estimate the net rate of carbohydrate oxidation, as previously described (22).
Statistical analysis was performed using the STATISTICA 6.0 for Windows (StatSoft Inc., Tulsa, OK) software. The data were first tested for normal distribution by using the Shapiro-Wilks test for normality. Leptin and adiponectin concentrations were not normally distributed, so a Kruskal-Wallis test was used to compare the above parameters between AN patients and the control group. As for the other variables, whose distribution was normal, Students t test for independent samples was used to evaluate the differences between the AN and control groups. Results are presented as mean and SD for all parameters. A level of significance of P < 0.05 was used for all data analyses.
| Results |
|---|
|
|
|---|
|
|
|
| Discussion |
|---|
|
|
|---|
The most original and striking result of the present study is that anorectic patients had higher adiponectin plasma levels, compared with normal-weight healthy female controls, despite that insulin sensitivity was lower in the AN group than in controls. This finding is quite surprising if it is taken into account that the closest correlate of plasma adiponectin has been shown to be the degree of insulin resistance (10); moreover, it has been demonstrated that administration of adiponectin increases insulin sensitivity in animal models (15). We do not have a clear-cut explanation for our apparently paradoxical findings; however, several hypotheses may be formulated.
Adiponectin has been shown to be suppressed in states of insulin resistance, such as type 2 diabetes and obesity (8, 10); however, it is largely unknown which factors might contribute to this down-regulation. Lower plasma adiponectin levels in obesity, despite that adipose tissue is the only source of this protein, suggest a negative feedback on adiponectin production. In this respect, several experimental evidences [including the demonstration that expression of adipogenic genes, in general, and adiponectin, in particular, from adipose tissue of animals and humans is suppressed or down-regulated in obesity and type 2 diabetes (8, 26)] argue for the existence of such a feedback inhibitory pathway. Therefore, body weight reduction would result in disinhibition and, consequently, elevation of adiponectin concentrations.
This negative feedback pathway between adipose tissue and adiponectin expression might explain higher plasma adiponectin levels in AN patients, as compared with age-matched, normal-weight female controls, that we found in the present study.
Indeed, Havel et al. (14) recently reported a significant increase of plasma adiponectin in young adult women in response to 7 d of energy restriction (
600 kcal/d); this study is of outstanding interest for us because the adiponectin-increasing effect of caloric restriction has been demonstrated in a group of normal-weight women, thus suggesting that weight loss is able to raise circulating adiponectin concentrations even in the absence of overweight or obesity.
Moreover, we cannot exclude a role of reduced leptin concentrations in determining the elevation of adiponectin plasma levels. Indeed, it is well known that there are relevant interactions between leptin and other cytokines; these interactions could result in an additive, synergistic, or even antagonistic effect, thus suggesting the existence of positive and negative feedback systems dependent on cytokine-cytokine interactions (27, 28).
Finally, it can be hypothesized that elevated circulating adiponectin concentrations might represent a compensatory mechanism for the reduced insulin-stimulated glucose metabolism in AN patients, compared with normal-weight controls.
Previous studies regarding insulin sensitivity in anorectic patients gave conflicting results. In particular, insulin-stimulated glucose disposal has been reported to be normal (29), enhanced (30, 31), or decreased (32) in AN subjects. In our study, we found a reduced insulin-stimulated glucose disposal in the AN group, with prevalent impairment of nonoxidative glucose metabolism and no difference in glucose oxidation, thus suggesting that insulin stimulates glucose oxidation more than glucose storage in AN patients. Nonoxidative glucose metabolism represents more than 90% storage of glucose as glycogen in muscle and, interestingly, lower glycogen concentrations have been reported in skeletal muscle of anorectic patients (33). Therefore, our results indicate that a nonoxidative pathway of glucose metabolism is resistant to the action of insulin in AN; a similar situation is commonly observed during prolonged starvation, i.e. a further condition characterized by lower sensitivity to insulin. Insulin resistance in anorectic patients may well be a compensatory response to energy deprivation; in fact, glucose metabolism is directed toward immediate oxidation more than storage.
The conflicting results of the studies addressing the issue of insulin sensitivity in AN may be attributable to differences in the techniques for evaluating insulin action; in particular, our finding of reduced insulin-stimulated glucose disposal in anorectic patients, as compared with normal-weight controls, is consistent with the only study in which insulin sensitivity was measured by the glucose clamp technique (32).
We cannot indicate, with certainty, what factor is responsible for the uncoupling between adiponectin plasma levels and insulin-mediated glucose metabolism; in this respect, we can hypothesize that some cytokines, such as TNF-
, may play an important role. Indeed, it has been demonstrated that plasma concentrations of TNF-
, referred to as a potential mediator of insulin resistance (34), are increased in anorectic patients independently of body fat, thus suggesting that the adipose tissue may not be the immediate source of this cytokine in AN (35). Overall, the above metabolic perturbation of anorectic patients may be interpreted, from a finalistic point of view, as a defensive mechanism directed to prevent such undernourished patients from hypoglycemia.
We are aware of the fact that a weak point of this study is the relevant difference of age, even though not statistically significant, between AN patients and normal-weight controls. However, we do not believe that this difference played a crucial role in relation to adiponectin and leptin concentrations, because there have been several studies that could not find a significant relationship of age with both adiponectin (36) and leptin (37) circulating levels.
This study also supports previous reports that anorectics have significantly lower levels of plasma leptin than normal (16, 38), thus suggesting that this cytokine is not involved in the reduction of food intake associated with AN, and that shifts of energy balance (either positive, i.e. body weight gain, or negative, i.e. body weight loss) are accompanied by changes in circulating leptin levels reflecting total body fat mass. Furthermore, it has been demonstrated that leptin concentrations decrease during nutritional deprivation more rapidly than would be expected on the basis of weight loss (39).
In conclusion, our study demonstrates that young women suffering from AN have higher adiponectin plasma levels and lower insulin-stimulated glucose disposal, with prevalent impairment of nonoxidative glucose metabolism, than normal-weight healthy female controls of similar age. The increase in adiponectin concentrations might be thought of as a compensatory mechanism for insulin resistance of AN patients, but further studies are needed to confirm this possibility.
| Acknowledgments |
|---|
| Footnotes |
|---|
Abbreviations: AN, Anorexia nervosa; BMI, body mass index; ob, obese gene.
Received August 1, 2002.
Accepted January 2, 2003.
| References |
|---|
|
|
|---|
B signaling through a cAMP-dependent pathway. Circulation 102:12961301
: direct role in obesity-linked insulin resistance. Science 259:8791
(TNF-
) and soluble TNF receptors in patients with anorexia nervosa. J Clin Endocrinol Metab 84:12261228This article has been cited by other articles:
![]() |
L. A. Kosmiski, P. Bacchetti, D. P. Kotler, S. B. Heymsfield, C. E. Lewis, M. G. Shlipak, R. Scherzer, and C. Grunfeld Relationship of Fat Distribution with Adipokines in Human Immunodeficiency Virus Infection J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 216 - 224. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tomoda, M. Yoshikawa, T. Itoh, S. Tamaki, A. Fukuoka, K. Komeda, and H. Kimura Elevated Circulating Plasma Adiponectin in Underweight Patients With COPD Chest, July 1, 2007; 132(1): 135 - 140. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Misra, K. K. Miller, J. Cord, R. Prabhakaran, D. B. Herzog, M. Goldstein, D. K. Katzman, and A. Klibanski Relationships between Serum Adipokines, Insulin Levels, and Bone Density in Girls with Anorexia Nervosa J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2046 - 2052. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Modan-Moses, D. Stein, C. Pariente, A. Yaroslavsky, A. Ram, M. Faigin, R. Loewenthal, E. Yissachar, R. Hemi, and H. Kanety Modulation of Adiponectin and Leptin during Refeeding of Female Anorexia Nervosa Patients J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1843 - 1847. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. McEntegart, B. Awede, M. C. Petrie, N. Sattar, F. G. Dunn, N. G. MacFarlane, and J. J.V. McMurray Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide Eur. Heart J., April 2, 2007; (2007) ehm033v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Housova, K. Anderlova, J. Krizova, D. Haluzikova, J. Kremen, T. Kumstyrova, H. Papezova, and M. Haluzik Serum Adiponectin and Resistin Concentrations in Patients with Restrictive and Binge/Purge Form of Anorexia Nervosa and Bulimia Nervosa J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1366 - 1370. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Misra, K. K. Miller, C. Almazan, K. Ramaswamy, A. Aggarwal, D. B. Herzog, G. Neubauer, J. Breu, and A. Klibanski Hormonal and Body Composition Predictors of Soluble Leptin Receptor, Leptin, and Free Leptin Index in Adolescent Girls with Anorexia Nervosa and Controls and Relation to Insulin Sensitivity J. Clin. Endocrinol. Metab., July 1, 2004; 89(7): 3486 - 3495. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tagami, N. Satoh, T. Usui, K. Yamada, A. Shimatsu, and H. Kuzuya Adiponectin in Anorexia Nervosa and Bulimia Nervosa J. Clin. Endocrinol. Metab., April 1, 2004; 89(4): 1833 - 1837. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Sivan, S. Mazaki-Tovi, C. Pariente, Y. Efraty, E. Schiff, R. Hemi, and H. Kanety Adiponectin in Human Cord Blood: Relation to Fetal Birth Weight and Gender J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5656 - 5660. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Monteleone, M. Fabrazzo, V. Martiadis, A. Fuschino, C. Serritella, N. Milici, and M. Maj Opposite Changes in Circulating Adiponectin in Women With Bulimia Nervosa or Binge Eating Disorder J. Clin. Endocrinol. Metab., November 1, 2003; 88(11): 5387 - 5391. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |